Acromegaly :: Options improving for patients with acromegaly and gigantism – endocrinology expert

Scientific, technological and medical advances made in the past two decades are leading to more definitive diagnoses, earlier and more effective treatment options and better outcomes for patients suffering from a condition called acromegaly, according to an article published in today’s issue of the New England Journal of Medicine and authored by a specialist in endocrinology at Cedars-Sinai Medical Center.

Ovarian Cancer :: Clumping protein linked to return of ovarian cancer

Johns Hopkins scientists have discovered that women treated for ovarian cancer are at increased risk of a rapid and potentially fatal recurrence if their tumor cells have high levels of a binding protein that triggers abnormal growth and slows down cell death, both hallmarks of malignancy.

Breast Cancer :: Efficacy of Pfizer’s Aromasin for early breast cancer

New data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 study, presented today at the San Antonio Breast Cancer Symposium, showed that postmenopausal women with hormone receptor-positive breast cancer who received Aromasin after five years of tamoxifen were 56 percent less likely to have a relapse of breast cancer than those who received placebo.

Lead :: Pros and cons of therapy for lead exposure

Lead chelation therapy can lessen learning and behavioral problems due to lead exposure, but the therapy adversely affected rats with no lead in their systems, a Cornell study shows. The finding has implications for the treatment of autistic children.

Stem Cell :: Cooperation needed for advancement of stem cell research

Tissue regeneration strategies, such as stem cell research, have undergone notable developments over the past two decades. However, an article in the journal, Artificial Organs, suggests that many challenges must be overcome before regenerative medicine is accepted as a viable science.

Breast Cancer :: Tykerb, lapatinib – novel breast cancer drug

A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital (MGH) Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack